Skip to main content
Fig. 2 | Orphanet Journal of Rare Diseases

Fig. 2

From: Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy

Fig. 2

NIS-LL muscle weakness progression in relation to baseline severity and the effect of treatment. Baseline NIS-LL muscle weakness scores of 5, 15, and 25 were chosen for illustration and were used as the zero time point. Values for Months 6, 12, and 18 were estimated using the linear mixed-effects model. NIS-LL Neuropathy Impairment Score − Lower Limbs; P-T placebo-to-tafamidis; T-T tafamidis-to-tafamidis

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172